iBio, Inc.
Pressemitteilungen
08.05.2012 Broad Patent Protection Granted for iBio Immunomodulator
16.04.2012 iBio to Present at the Wells Fargo Securities 2012 Healthcare Conference
10.04.2012 iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
27.03.2012 Vaccine Applications of iBio's Proprietary Lichenase Technology Reported at International Conference
21.03.2012 iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
07.03.2012 iBio to Present at the 24th Annual ROTH Conference on March 14
29.02.2012 Patent Issued on Fusion-Protein Vaccine Technology
27.01.2012 iBio, Inc. Listing Deficiency Resolved
10.01.2012 iBio, Inc. Prices $10 Million Public Offering
09.01.2012 iBio, Inc. Announces Proposed Public Offering
30.11.2011 iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
17.11.2011 iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
31.10.2011 iBio Announces New US Patent for iBioLaunch™ Technology
05.10.2011 iBio Announces Production of Biosimilar Rituximab with its iBioLaunch™ Technology
04.08.2011 iBio Announces Malaria Vaccine Milestone Achievement on its iBioLaunch™ Platform
11.07.2011 iBio Announces Plasma Protein Development on its iBioLaunch™ Platform
28.06.2011 iBio, Inc. Selected for Russell Microcap Index
22.06.2011 Jules A. Müsing Joins iBio’s Board of Directors
07.06.2011 iBio to Host Open House for Sell-Side Analysts and Institutional Investors
02.06.2011 iBio Announces Positive H1N1 Influenza Vaccine Clinical Trial Results
31.05.2011 iBio Invited to Present at the Wells Fargo Securities Healthcare Conference
26.05.2011 iBio Announces Successful Production of Critical Hookworm Vaccine Antigen
10.05.2011 iBio Announces Presentation at Noble Financial Conference
05.05.2011 iBio Announces Engagement of CBR International for Fabry Disease Product and Clinical Development
03.05.2011 iBio Appoints Douglas Beck Chief Financial Officer
13.04.2011 iBioLaunch™ Technology Versatility Confirmed in Peer-Reviewed Scientific Publications
23.02.2011 iBio Announces Acquisition of Fabry Disease Orphan Drug Designation and Development Program
03.01.2011 iBio Common Stock Approved for Listing on the NYSE Amex Exchange Under the Symbol IBIO
06.12.2010 Another Clinical Trial Commenced for a Product Based on iBioLaunch Technology
27.10.2010 iBio erhält Finanzierung von Privatinvestoren
20.09.2010 Clinical Trial to Commence for Product Based upon Transformative iBioLaunch Technology
01.09.2010 iBio and Fraunhofer Execute Business Development and Marketing Agreement with GE Healthcare
05.08.2010 Arthur Y. Elliott, PhD, Joins iBio's Board of Directors